Interpreting and communicating risk of medications in pregnancy, using SSRIs as an example

Jennita Reefhuis, William Bobo, Eugene Van Puijenbroek, Leyla Sahin

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    Background: Often we consider publishing our research as the last step in the process. However, women considering pregnancy, women who are pregnant and health care providers caring for these women need to be able to interpret and use our research to make treatment decisions for their health and the infant's. We may consider ourselves to be scientists and not policy makers, but, if we do not clearly describe and interpret our results others will interpret it for us. This abstract is submitted on behalf of the Medications in Pregnancy SIG. Objectives: To be aware of the challenges that health care providers, who care for women with chronic conditions such as depression, face. To learn how to write scientific manuscripts and press releases that are as helpful as possible for health care providers, the general public and policy makers. Description: A moderator and four speakers will discuss the challenges of interpreting the scientific data that is out there. The first speaker will briefly discuss the existing literature on SSRIs and major birth defects, and the potential reasons for conflicting results, or conflicting interpretation of results. The second speaker will provide the clinical perspective of a provider who treats women with depression who might want to get pregnant or who already are pregnant. Someone from a teratogen information center will provide insight into what aspects of communication are important to inform and educate in a transparent way, for instance by using absolute risks. Someone from a regulatory agency will discuss what aspects of publications on medications in pregnancy are most important to them as they regulate. Lastly a journalist will share with us what factors influence whether a paper will be considered for coverage in a media outlet and what information is useful for them to write their articles. Participants can be involved by providing specific examples and working together to come up with improved ways to present data.
    Original languageEnglish
    Pages (from-to)371-372
    Number of pages2
    JournalPharmacoepidemiology and Drug Safety
    Volume22
    Issue numbers1
    Publication statusPublished - Oct-2013

    Keywords

    • teratogenic agent
    • drug therapy
    • pregnancy
    • pharmacoepidemiology
    • risk management
    • risk
    • female
    • human
    • health care personnel
    • policy
    • publishing
    • publication
    • scientist
    • interpersonal communication
    • information center
    • birth defect
    • infant
    • health

    Cite this